City Therapeutics (CTY) news

City Therapeutics opens at $23, IPO at $18

Trading released/resumed: (CTY) Reason not available

Trading in the shares of City of London Investment Trust PLC (CTY) has resumed following a previously unexplained trading halt. While the specific reason for the suspension remains undisclosed, trading halts are typically implemented by exchanges to ensure market fairness and stability, often in…

City Therapeutics shares indicated at $22; IPO price $18

City Therapeutics, a biotechnology firm specializing in RNA interference therapeutics, has drawn attention ahead of its anticipated initial public offering (IPO). According to recent market activity, the company’s shares are currently indicated at $22, surpassing the expected IPO price of $18. This…

City Therapeutics shares indicated at $20.25; IPO price $18

City Therapeutics (Nasdaq: CTY) began trading on October 16, 2026, with shares opening at $20.25 , above the IPO price of $18 per share. The company, a clinical-stage biotechnology firm, raised capital through its IPO as part of a broader trend of biotech firms leveraging the fall IPO window. The…

City Therapeutics said to placed no IPO shares to 50% of orders

City Therapeutics (Nasdaq: CTY) has reportedly allocated no IPO shares to 50% of orders, according to recent reports. The company, which listed on the NASDAQ on October 16, 2026, priced its shares in the range of $17.00 to $19.00 per share, offering 9.72 million shares in total . This allocation…